Ratings Daihan Pharmaceutical Co.,Ltd.

Equities

End-of-day quote Korea S.E. Other stock markets 03:30:00 17/05/2024 am IST			5-day change	1st Jan Change
28,800 ^KRW	+0.88%		+0.70%	+3.78%

2023	Daihan Pharmaceutical Co.,Ltd.(KOSDAQ:A023910) dropped from S&P Global BMI Index	CI
2023	Daihan Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Thanks to a sound financial situation, the firm has significant leeway for investment.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 794.95 for the 2024 fiscal year.
The company appears to be poorly valued given its net asset value.
Given the positive cash flows generated by its business, the company's valuation level is an asset.

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
DAIHAN PHARMACEUTICAL CO.,LTD.	+3.78%	125M		-
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.63%	44.11B		B-
OTSUKA HOLDINGS CO., LTD.	+23.03%	22.71B		B+
SANDOZ GROUP AG	+18.22%	15.15B		-
CIPLA LIMITED	+12.66%	13.56B		B+
ZYDUS LIFESCIENCES LIMITED	+60.18%	12.7B		B
ONO PHARMACEUTICAL CO., LTD.	-10.02%	6.84B		B+
THE MEDICINES COMPANY	-0.05%	6.79B	-	-
STADA ARZNEIMITTEL	-8.87%	5.73B	-	-
ASPEN PHARMACARE HOLDINGS LIMITED	+12.92%	5.63B		B+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality